Business

Nuclear Medicine and Radiopharmaceutical Manufacturing Market is estimated to be more than USD 6 billion in 2030

The recent surge in the demand of radiopharmaceuticals for diagnostic and therapeutic applications, coupled with the introduction of theranostics, has opened up opportunities for companies having capabilities to manufacture nuclear medicine and radiopharmaceuticals

Roots Analysis is pleased to announce the publication of its recent study, titled, “Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030

The report provides a detailed study on the current market landscape and future potential of the companies having the capabilities to manufacture radiopharmaceuticals. In addition, the study features an in-depth analysis, highlighting the capabilities of a diverse set of industry stakeholders. Amongst other elements, the report features the following:

  • A detailed assessment of the current market landscape with respect to the players (industry and non-industry) involved in manufacturing radiopharmaceuticals.
  • An insightful four-dimensional comparison of the radiopharmaceutical manufacturers.
  • Tabulated profiles of key industry players based in North America, Europe and Asia-Pacific (shortlisted based on the company size of the players).
  • An analysis of recent partnerships and collaborations inked in this domain since 2017.
  • A detailed discussion on the supply chain model of medical isotope Mo-99 (Tc-99m).

Key Market Insights

  • Close to 130 industry and non-industry players, across the globe, claim to have the necessary expertise and supporting infrastructure to manufacture a wide variety of radioisotopes, for in-house use, or as a contract service
  • The market is fragmented, featuring the presence of companies in both developed and developing nations, which are capable of manufacturing radiopharmaceuticals for various applications at different scales of production
  • The growing interest in this field is reflected in the yearly growth in partnership activity; the majority of deals inked in the recent past include manufacturing and supply agreements for various types of radiopharmaceuticals
  • Stakeholders are actively expanding their capabilities in order to enhance their respective nuclear medicine and radiopharmaceutical manufacturing capabilities and, thereby, maintain a competitive edge in this industry
  • Case Study: The decay product of Mo-99, Tc-99m, is used in majority of the radioactivity-based diagnostic applications in the US; reactors in the European region alone contribute to 60% of the global production capacity
  • In the long-term, the forecasted opportunity is anticipated to be higher for radioisotopes intended for diagnostic applications, mostly for use in the field of cardiology, with North America holding the dominant position

SPECT and beta-emitters are anticipated to generate the majority share of revenues across diagnostic and therapeutic applications, respectively, for both in-house use and radiopharmaceutical supply contracts

Request for Customization:

https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing/request-customization.html

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Target Therapeutic Area

  • Cardiology
  • Neurology
  • Oncology
  • Thyroid
  • Others

Application Area

  • Diagnostic
  • Therapeutic

Type of Diagnostic Radiopharmaceuticals

  • PET
  • SPECT

Type of Therapeutic Radiopharmaceuticals

  • Alpha Emitters
  • Beta Emitters
  • Others

Purpose of Production

  • In-House
  • Outsourcing

Key Geographical Region

  • North America
  • Europe
  • Asia-Pacific and the Rest of the World

Transcripts of interviews held with the following senior level representatives of stakeholder companies

  • J James Davis, Vice President Quality / R&D, Shertech Laboratories
  • Andreas Fotopoulos, Professor of Nuclear Medicine, University of Ioannina Medical School
  • Jan Pruim, Professor of Medical Imaging / Nuclear Medicine Physician, University Medical Center of Groningen
  • Michael van Dam, Professor, Crump Institute for Molecular Imaging, Molecular & Medical Pharmacology
  • Anonymous, ITM Isotopen Technologien München

Key companies covered in the report

  • Advanced Accelerator Applications
  • Belgian Nuclear Research Center (SCK•CEN)
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Curium Pharma
  • DuChemBio
  • Eckert & Ziegler
  • Eczacibasi-Monrol
  • GE Healthcare
  • Jubilant DraxImage
  • Lantheus Medical Imaging
  • Nihon Medi-Physics
  • Nordion
  • PETNET Solutions
  • SinoTau Pharmaceuticals
  • SOFIE

Request for Sample:

https://www.rootsanalysis.com/reports/nuclear-medicine-and-radiopharmaceuitcals-manufacturing/request-customization.html

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Also Visit Our Latest Publication

Human Microbiome Market

In Silico / Computer-Aided Drug Discovery Services Market

Antibody Contract Manufacturing Market

Biopharma Contract Manufacturing Market

Cell Therapy Manufacturing Market